Literature DB >> 3561525

The effects on Schild regressions of antagonist removal from the receptor compartment by a saturable process.

T P Kenakin, D Beek.   

Abstract

A theoretical model of the effects of a saturable removal mechanism for an antagonist diffusing into the receptor compartment of a tissue is used to calculate expected deviations in Schild regressions. At concentrations of antagonist which do not saturate the removal mechanism, there can be a deficit of antagonist in the receptor compartment as compared to the concentration of antagonist bathing the tissue. This results in a shift to the right of the Schild regression and a corresponding underestimation of antagonist potency. The model predicts that as the concentration of antagonist exceeds the Km for removal (saturation of the removal process), this concentration deficit is eliminated, resulting in a proportionate increase in antagonist concentration at the receptor and a concomitant increase in receptor antagonism. This results in a steepening of the Schild regression; the slope in the region of saturation is greater than one. Experimental evidence in support of this model was found in studies of the antagonism of responses to bethanechol by atropine in rabbit ileum; this species is known to have an atropinesterase capable of hydrolyzing atropine. The Schild regression for atropine was curvilinear with an overall slope of 1.42 (1.34-1.5) and pKB = 8.5 (8.36-8.8); in the ileum from guinea pigs, a species which does not possess this enzyme, the Schild regression for atropine was linear, had a slope not significantly different from unity (1.1; 0.95-1.2) and a pKb of 9.0 (8.9-9.2). The slope of the regression in rabbit ileum was corrected to unity by the addition of an excess concentration of methylbutyrate, an alternate substrate for atropinesterase.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3561525     DOI: 10.1007/BF00177709

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  10 in total

1.  The kinetics of enzyme action and inhibition in intact tissues and tissue slices, with special reference to cholinesterase.

Authors:  A L Green
Journal:  J Pharm Pharmacol       Date:  1976-04       Impact factor: 3.765

2.  Cumulative dose-response curves. II. Technique for the making of dose-response curves in isolated organs and the evaluation of drug parameters.

Authors:  J M VAN ROSSUM
Journal:  Arch Int Pharmacodyn Ther       Date:  1963

3.  The use and limitations of atropine for pharmacological studies on autonomic effectors.

Authors:  N AMBACHE
Journal:  Pharmacol Rev       Date:  1955-12       Impact factor: 25.468

4.  [The purification and characterization of atropine esterase from rabbit liver microsomes (author's transl)].

Authors:  P Moog; K Krisch
Journal:  Hoppe Seylers Z Physiol Chem       Date:  1974-05

Review 5.  Effects of unstirred layers on membrane phenomena.

Authors:  P H Barry; J M Diamond
Journal:  Physiol Rev       Date:  1984-07       Impact factor: 37.312

6.  The positive inotropic effect of (-)-noradrenaline and (+/-)-isoprenaline after chemical sympathectomy: evidence in favour of differences at a postsynaptic site.

Authors:  F Ebner; H Fleig; U Trendelenburg
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1981-02       Impact factor: 3.000

7.  Some quantitative uses of drug antagonists.

Authors:  O ARUNLAKSHANA; H O SCHILD
Journal:  Br J Pharmacol Chemother       Date:  1959-03

8.  The role of uptake of noradrenaline of its positive inotropic effect in relation to muscle geometry. Statistical evaluation.

Authors:  F Ebner; D R Waud
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1978-05       Impact factor: 3.000

9.  CAT HEART MUSCLE IN VITRO. V. DIFFUSION THROUGH A SHEET OF RIGHT VENTRICLE.

Authors:  E PAGE; R S BERNSTEIN
Journal:  J Gen Physiol       Date:  1964-07       Impact factor: 4.086

10.  THE OCCURRENCE AND DISTRIBUTION OF ATROPINESTERASE, AND THE SPECIFICITY OF TROPINESTERASES.

Authors:  D Glick; S Glaubach
Journal:  J Gen Physiol       Date:  1941-11-20       Impact factor: 4.086

  10 in total
  9 in total

1.  The presence of atropinesterase activity in animal plasma.

Authors:  Patrick K Harrison; John E H Tattersall; Ed Gosden
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-05-03       Impact factor: 3.000

2.  Positive cooperative interaction of quaternary anticholinergics with functional muscarinic receptors in bovine tracheal smooth muscle.

Authors:  A F Roffel; C R Elzinga; W Beltman; E J van Tintelen; J Zaagsma
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-03       Impact factor: 3.000

3.  Agonist and antagonist characterization of a putative adrenoceptor with distinct pharmacological properties from the alpha- and beta-subtypes.

Authors:  R A Bond; D E Clarke
Journal:  Br J Pharmacol       Date:  1988-11       Impact factor: 8.739

4.  Selective enhancement of fentanyl-induced antinociception by the delta agonist SNC162 but not by ketamine in rhesus monkeys: Further evidence supportive of delta agonists as candidate adjuncts to mu opioid analgesics.

Authors:  Matthew L Banks; John E Folk; Kenner C Rice; S Stevens Negus
Journal:  Pharmacol Biochem Behav       Date:  2010-08-03       Impact factor: 3.533

Review 5.  pA2 values for antagonists of platelet activating factor on aggregation of rabbit platelets.

Authors:  S R O'Donnell; C J Barnett
Journal:  Br J Pharmacol       Date:  1988-06       Impact factor: 8.739

Review 6.  Drug Design Targeting the Muscarinic Receptors and the Implications in Central Nervous System Disorders.

Authors:  Chad R Johnson; Brian D Kangas; Emily M Jutkiewicz; Jack Bergman; Andrew Coop
Journal:  Biomedicines       Date:  2022-02-07

7.  Pharmacological analysis of agonist-antagonist interactions at acetylcholine muscarinic receptors in a new urinary bladder assay.

Authors:  P A Durant; N P Shankley; N J Welsh; J W Black
Journal:  Br J Pharmacol       Date:  1991-09       Impact factor: 8.739

8.  In vitro characterization of tripitramine, a polymethylene tetraamine displaying high selectivity and affinity for muscarinic M2 receptors.

Authors:  A Chiarini; R Budriesi; M L Bolognesi; A Minarini; C Melchiorre
Journal:  Br J Pharmacol       Date:  1995-04       Impact factor: 8.739

9.  Clearance of oxytocin and its potentially enzyme resistant analogues in the OXT-receptor compartment of the potassium depolarized rat myometrium.

Authors:  Vladimir Pliska; Guido Jutz
Journal:  J Pept Sci       Date:  2021-10-14       Impact factor: 2.408

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.